Edita Navratilova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3112233/publications.pdf

Version: 2024-02-01

54 papers	2,728 citations	218592 26 h-index	189801 50 g-index
55 all docs	55 docs citations	55 times ranked	2960 citing authors

#	Article	IF	Citations
1	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain, 2023, 146, 1186-1199.	3.7	8
2	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia, 2022, 42, 197-208.	1.8	14
3	Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons. Molecular Brain, 2022, 15, 10.	1.3	14
4	Time-Dependent Changes in Protein Composition of Medial Prefrontal Cortex in Rats with Neuropathic Pain. International Journal of Molecular Sciences, 2022, 23, 955.	1.8	6
5	Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain, 2022, 145, 2894-2909.	3.7	20
6	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. Cephalalgia, 2022, , 033310242210998.	1.8	3
7	Kappa Opioid Receptor Blockade in the Amygdala Mitigates Pain Like-Behaviors by Inhibiting Corticotropin Releasing Factor Neurons in a Rat Model of Functional Pain. Frontiers in Pharmacology, 2022, 13, .	1.6	12
8	Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. Cellular and Molecular Neurobiology, 2021, 41, 949-960.	1.7	6
9	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. Cephalalgia, 2021, 41, 305-317.	1.8	21
10	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. Cephalalgia, 2021, 41, 749-759.	1.8	17
11	Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors. Neuropharmacology, 2021, 185, 108456.	2.0	25
12	Cognition in the Chronic Pain Experience: Preclinical Insights. Trends in Cognitive Sciences, 2021, 25, 365-376.	4.0	38
13	Chronic Pain Produces Reversible Memory Deficits That Depend on Task Difficulty in Rats. Journal of Pain, 2021, 22, 1467-1476.	0.7	5
14	Sexual dimorphism in functional pain syndromes. Science Translational Medicine, 2021, 13, eabj7180.	5.8	12
15	Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. Cell Reports, 2021, 37, 109933.	2.9	27
16	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 68-78.	1.8	15
17	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. Pain, 2020, 161, 609-618.	2.0	34
18	An Emerging Role for Prolactin in Female-Selective Pain. Trends in Neurosciences, 2020, 43, 635-648.	4.2	25

#	Article	IF	Citations
19	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia, 2020, 40, 1535-1550.	1.8	17
20	Amygdala, neuropeptides, and chronic pain-related affective behaviors. Neuropharmacology, 2020, 170, 108052.	2.0	109
21	Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 903-912.	1.8	24
22	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 892-902.	1.8	47
23	The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. Science Translational Medicine, 2020, 12, .	5.8	46
24	Supraspinal Opioid Circuits Differentially Modulate Spinal Neuronal Responses in Neuropathic Rats. Anesthesiology, 2020, 132, 881-894.	1.3	10
25	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia, 2019, 39, 1762-1775.	1.8	66
26	Opioid analgesics pass the acid test. Lancet, The, 2019, 393, 1579-1581.	6.3	0
27	Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. Pain, 2019, 160, 824-832.	2.0	75
28	Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously. Neuron, 2019, 101, 353-355.	3.8	42
29	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. Pain, 2019, 160, 1614-1621.	2.0	45
30	Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia, 2019, 39, 617-625.	1.8	26
31	Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain. Pain, 2018, 159, 919-928.	2.0	71
32	Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. Molecular Pain, 2018, 14, 174480691875640.	1.0	57
33	Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system. Molecular Pain, 2018, 14, 174480691875493.	1.0	12
34	Shared Mechanisms of Chronic Pain and Emotional-Motivational Problems: From Basic Science to the Clinics. Pain Research and Management, 2018, 2018, 1-2.	0.7	8
35	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. Pain, 2018, 159, 2512-2521.	2.0	46
36	Emotional and Motivational Pain Processing: Current State of Knowledge and Perspectives in Translational Research. Pain Research and Management, 2018, 2018, 1-12.	0.7	74

#	Article	IF	Citations
37	Engagement of kappa opioid system in the right amygdala diminishes diffuse noxious inhibitory controls (DNIC). Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-19.	0.0	0
38	Reward, motivation, and emotion of pain and its relief. Pain, 2017, 158, S43-S49.	2.0	119
39	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia, 2017, 37, 780-794.	1.8	70
40	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain, 2017, 158, 2386-2395.	2.0	74
41	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. Cephalalgia, 2017, 37, 1350-1372.	1.8	31
42	Positive emotions and brain reward circuits in chronic pain. Journal of Comparative Neurology, 2016, 524, 1646-1652.	0.9	67
43	Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. Pain, 2016, 157, 2731-2738.	2.0	38
44	Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3716-3720.	1.0	14
45	Endogenous Opioid Activity in the Anterior Cingulate Cortex Is Required for Relief of Pain. Journal of Neuroscience, 2015, 35, 7264-7271.	1.7	154
46	Brain Circuits Encoding Reward from Pain Relief. Trends in Neurosciences, 2015, 38, 741-750.	4.2	174
47	Reward and motivation in pain and pain relief. Nature Neuroscience, 2014, 17, 1304-1312.	7.1	370
48	Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: A potential biomarker of efficacy. Pain, 2014, 155, 1659-1666.	2.0	66
49	Evaluation of reward from pain relief. Annals of the New York Academy of Sciences, 2013, 1282, 1-11.	1.8	109
50	Pain relief produces negative reinforcement through activation of mesolimbic rewardâ€“valuation circuitry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20709-20713.	3.3	258
51	Contribution of PKMÎ¶-dependent and independent amplification to components of experimental neuropathic pain. Pain, 2012, 153, 1263-1273.	2.0	47
52	Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner. European Journal of Pharmacology, 2008, 584, 272-277.	1.7	30
53	Quantitative Evaluation of Human Î´ Opioid Receptor Desensitization Using the Operational Model of Drug Action. Molecular Pharmacology, 2007, 71, 1416-1426.	1.0	17
54	Morphine promotes phosphorylation of the human Î´-opioid receptor at serine 363. European Journal of Pharmacology, 2005, 519, 212-214.	1.7	11